Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/jmph-136

Inflammatory Back Pain: Integrated Approaches in Physical Therapy, Nursing, and Laboratory Management

Ahmed Moner Alqerafi[(1)], Mohammad Abdullah Mubarak Almarwan[(2)], Khaled Alnashmi F Alanazi[(3)], Mohammed Yahya Abdu Rayyani[(4)], Thikrayat Mohammed Alaithan[(5)], Fahad Sulaiman Almousa[(6)], Fozeh Menhy Alrewily[(7)], Albandari Sulaiman A Al Nafisah[(8)], Maryam Thalab Salman Al Dhafery[(9)], Salem Mushari Saleh Al Dughman[(10)], Aysha Ali Hamoud Alsalman[(10)], Zainab Haider Alsharfa[(11)]

[(1)]Maternity and Children's Hospital, Ministry of Health, Saudi Arabia
[(2)]Ministry of Health, Riyadh Region, Saudi Arabia
[(3)]Moh-Riyadh Second Health Cluster, Ministry of Health, Saudi Arabia
[(4)]Eradah And Psychiatric Hospital-Jazan, Ministry of Health, Saudi Arabia
[(5)]Oyun City Hospital In Alahsaa, Ministry of Health, Saudi Arabia
[(6)]King Fahad Medical City, Ministry of Health, Saudi Arabia
[(7)]Hafr Al-Batin Central Hospital, Ministry of Health, Saudi Arabia
[(8)]Moh Almalga Primary Heath Care Nursing, Ministry of Health, Saudi Arabia
[(9)]Mental Health Hospital, Ministry of Health, Saudi Arabia
[(10)]Eastern Health Cluster, Ministry of Health, Saudi Arabia
[(11)]Ministry of Health, Saudi Arabia

Abstract

Background: Inflammatory Back Pain (IBP) is a clinical syndrome characterized by chronic axial spinal pain, distinct from mechanical back pain. It is strongly associated with seronegative spondyloarthropathies (SpA) like ankylosing spondylitis and, if unmanaged, can lead to progressive structural damage and significant morbidity.
Aim: This article aims to delineate the integrated, multidisciplinary approach required for the effective diagnosis, management, and long-term care of IBP. It emphasizes early recognition to prevent irreversible complications and improve patient outcomes.
Methods: Management involves a coordinated strategy combining early rheumatologist referral, pharmacotherapy (NSAIDs, biologic DMARDs like TNF or IL-17 inhibitors), and non-pharmacologic interventions. The latter includes structured physical therapy, patient education, and lifestyle modifications. Diagnosis relies on clinical criteria (e.g., chronicity, morning stiffness, improvement with exercise), supported by laboratory tests (HLA-B27, inflammatory markers) and advanced imaging (MRI).
Results: A multidisciplinary approach effectively controls symptoms, preserves spinal mobility, and improves quality of life. However, under-diagnosis and delayed treatment can lead to complications including osteoporosis, fractures, spinal deformity, and increased cardiovascular risk. Early intervention is critical for a favorable prognosis.
Conclusion: Successful management of IBP hinges on an interprofessional model integrating specialist medical care, targeted pharmacotherapy, structured rehabilitation, and patient education to mitigate disease progression and systemic complications.
Keywords: Inflammatory Back Pain, Spondyloarthropathy, Ankylosing Spondylitis, Physical Therapy, Multidisciplinary Care, Biologics..

1. Introduction

Inflammatory back pain (IBP) denotes a clinical syndrome characterized by persistent axial spinal discomfort that predominantly involves the sacroiliac joints and the vertebral column. It is distinguished from mechanical etiologies of back pain by a constellation of clinical features rather than by a single pathognomonic sign. Although IBP demonstrates a strong epidemiological and mechanistic association with inflammatory spondyloarthropathies, its presence alone does not establish a definitive diagnosis of any specific rheumatologic disorder. Rather, IBP functions as a syndrome that raises the pretest probability for underlying inflammatory disease and thereby directs further diagnostic evaluation. Pain distribution and pattern provide essential discriminatory information in the clinical assessment of IBP. Pain is classically axial, centered in the lumbar spine but often extending to the thoracolumbar junction and the sacroiliac regions. Patients may report pain that alternates between the left and right buttock, a phenomenon that reflects intermittent sacroiliac joint involvement and may aid in distinguishing inflammatory processes from localized mechanical lesions. The temporal characteristics of pain are equally informative. IBP

*Corresponding author e-mail: ahalqerafi@moh.gov.sa (Ahmed Moner Alqerafi).
Receive Date: 26 November 2024, Revise Date: 26 December 2024, Accept Date: 31 December 2024

typically exhibits an insidious onset with gradual progression over weeks to months. The pain commonly persists for extended intervals, with a duration of three months or longer serving as a practical threshold to suspect an inflammatory origin rather than an acute mechanical insult [1][2].

Demographic and historical elements contribute substantially to the diagnostic formulation. Onset of symptoms before the fourth decade of life represents a frequent pattern in IBP populations and informs risk stratification during outpatient evaluation. Young age at onset, combined with chronicity and the described axial distribution, should prompt clinicians to pursue targeted inquiry into systemic features and extraarticular manifestations that may accompany seronegative spondyloarthropathies. Morning stiffness is a hallmark clinical symptom that differentiates IBP from mechanical low back pain. Patients with inflammatory pain commonly experience marked stiffness upon waking that improves with activity and movement. The diurnal variation characterized by morning immobility followed by progressive loosening with exercise reflects the underlying inflammatory milieu and its modulation by mechanical activity [1][2]. The relationship between IBP and established inflammatory disorders is well recognized yet heterogeneous. Ankylosing spondylitis exemplifies the prototypical diagnosis associated with IBP, but similar axial inflammatory manifestations occur in a spectrum of seronegative spondyloarthropathies. Psoriatic arthritis, enteropathic arthropathies associated with inflammatory bowel disease, juvenile idiopathic arthritis with axial involvement, and reactive arthritis each may present with axial pain phenotypes that overlap clinically with classical ankylosing disease. The presence of concomitant peripheral arthritis, enthesitis, uveitis, cutaneous plaques, or gastrointestinal symptoms can increase diagnostic specificity and inform subsequent rheumatologic workup. Nevertheless, a subset of patients will manifest IBP in the absence of sufficient criteria to classify a specific disorder. These undifferentiated presentations require longitudinal surveillance, since phenotypic evolution or the emergence of diagnostic biomarkers may unfold over time [3][4].

The diagnostic challenge posed by IBP necessitates a systematic and iterative approach. Initial clinical recognition rests on careful history taking and focused physical examination designed to elicit axial tenderness, reduced spinal mobility, and features of inflammatory back pain such as morning stiffness and improvement with exercise. Subsequent evaluation commonly involves laboratory and imaging modalities aimed at corroborating clinical suspicion and excluding alternative diagnoses. While serologic testing and radiographic imaging have roles in identifying objective evidence of inflammation or structural change, early-stage inflammatory processes may be radiographically occult and require advanced imaging or longitudinal reassessment. The clinician must therefore integrate temporal symptom patterns, demographic risk factors, and associated systemic signs into a probabilistic model that guides investigation and referral. In sum, inflammatory back pain constitutes a clinically significant syndrome that merits heightened diagnostic vigilance when presented with axial localization, chronicity of three months or more, early adult onset, insidious progression, and characteristic morning stiffness alleviated by activity. Its strong but nonexclusive association with seronegative spondyloarthropathies obliges clinicians to maintain a broad differential diagnosis while pursuing targeted evaluation for inflammatory disease. Recognition of undifferentiated cases and the potential for diagnostic conversion underscores the need for structured follow-up and timely rheumatologic consultation when features suggest an evolving systemic process [1][2][3][4].

Etiology:

The etiology of inflammatory back pain frequently converges on seronegative spondyloarthropathies, a group of disorders in which systemic immune activation precipitates localized axial inflammation. Genetic predisposition, most notably HLA-B27 carriage, increases susceptibility and shapes immune responses, but genetic factors do not fully account for disease onset. Environmental triggers, including microbial antigens and alterations in the gut microbiome, interact with genetic susceptibility to initiate and perpetuate immune activation. Mechanical stress at entheses and axial joints can amplify local inflammatory signaling, linking biomechanical factors to immunopathology. Together, these elements create a milieu in which systemic inflammation localizes to spinal and sacroiliac structures and produces the clinical phenotype of chronic axial pain. At the cellular and molecular level, persistent activation of innate and adaptive immune pathways drives the pathologic process. Proinflammatory cytokines such as tumor necrosis factor and interleukin-17 orchestrate recruitment and activation of immune effector cells within the enthesis, synovium, and subchondral bone. These cytokines propagate a cycle of inflammation that alters local cell populations and signaling networks. The result is sustained production of mediators that favor osteoclastogenesis and bone resorption in some microenvironments while promoting aberrant osteoblast activity and new bone formation in others. This paradoxical pattern of concomitant bone loss and pathologic bone formation underlies the complex radiographic and structural manifestations seen in advanced disease [2].

The structural consequences of chronic inflammation provide a mechanistic explanation for the progressive, insidious pain characteristic of IBP.

Repeated inflammatory insults at vertebral corners and entheses foster erosion, syndesmophyte development, and eventual ankylosis. Radiographic evidence of vertebral fusion and bridging ossification exemplifies the late structural phenotype that follows prolonged inflammatory activity. These changes reduce spinal mobility, alter load distribution, and perpetuate nociceptive inputs, thereby sustaining chronic pain. Imaging findings have guided experimental and clinical research by linking specific inflammatory mediators and cellular pathways to observable structural outcomes, thereby identifying targets for therapeutic intervention [1][5]. Understanding etiology therefore requires an integrated model that incorporates host genetics, environmental exposures, mucosal immune perturbations, mechanical stress, and defined cytokine networks. This model explains both the initiation of axial inflammation and its progression to structural damage. It also frames current therapeutic strategies that target TNF, IL-17, and related pathways to interrupt the inflammatory cascade, reduce symptoms, and limit structural progression. Continued research into the drivers of enthesial inflammation, the role of the microbiome, and the molecular determinants of pathological bone remodeling remains essential to refine disease-modifying approaches and to prevent the transition from inflammatory activity to irreversible structural change [1][5].

Epidemiology:

The epidemiology of inflammatory back pain (IBP) reflects a complex relationship between population genetics, diagnostic methodology, and associated inflammatory diseases. Estimates suggest that the prevalence of IBP among adults aged 20 to 69 in the United States ranges from 5% to 6%, indicating that a notable portion of the population experiences chronic back pain with inflammatory characteristics [6]. Despite this, the prevalence of diagnosed spondyloarthropathies is significantly lower, typically between 0.9% and 1.4%. This disparity suggests that many cases of IBP may occur independently of classical seronegative spondyloarthropathies or represent early, subclinical, or atypical presentations of such conditions. Regional variation in IBP prevalence highlights the influence of genetic and environmental factors. In Asian populations, for instance, the reported incidence of ankylosing spondylitis is markedly lower, around 0.001%, and only about 36% of individuals with IBP meet diagnostic criteria for spondyloarthropathy [7]. Such findings point to possible differences in HLA-B27 allele frequency, environmental exposures, and diagnostic awareness across populations. The genetic heterogeneity and differing thresholds for clinical investigation may contribute to underdiagnosis or misclassification, especially in regions where access to rheumatologic evaluation is limited. Consequently, these data reinforce the need for consistent diagnostic frameworks to ensure accurate cross-population comparisons [7].

In the United Kingdom, studies have identified a minimum prevalence of IBP between 1.7% and 3.4% in primary care settings [6], reflecting a lower detection rate compared with the United States. Similarly, epidemiological research in Mexico documented a prevalence of 3% within the adult population [6]. These findings underscore variability in clinical recognition, as diagnostic criteria—such as the Calin, Berlin, or Assessment of Spondyloarthritis International Society (ASAS) criteria—produce different prevalence estimates depending on their sensitivity and specificity. Despite methodological differences, most studies converge on a prevalence range below 8%, indicating that IBP, while relatively common, remains underdiagnosed and often underreported within clinical practice.



Figure-1: Inflammatory Back pain algorithm.

Demographic analyses provide additional insights into population distribution patterns. In one large U.S. study, IBP was more prevalent among non-Hispanic white individuals (5.9%) than among non-Hispanic black individuals (3.3%), suggesting a potential genetic contribution to disease susceptibility or differences in healthcare access [8]. However, current evidence does not show substantial variation in IBP prevalence between men and women or among different age groups within adult populations. This uniformity contrasts with diseases like ankylosing spondylitis, which display a pronounced male predominance, suggesting that IBP may represent a broader and more inclusive clinical spectrum. The observed differences in IBP prevalence across ethnic, geographic, and demographic groups point to the multifactorial nature of its development and diagnosis. Variability in healthcare infrastructure, diagnostic tools, and public awareness contributes to inconsistencies in epidemiological data. As research advances, integrating genetic screening, imaging modalities, and standardized clinical criteria may help close the gap between IBP prevalence and confirmed spondyloarthropathy diagnoses. Understanding these epidemiological patterns remains crucial for developing targeted screening strategies, early intervention programs, and culturally adapted management approaches to reduce the global burden of inflammatory back pain [8].

Pathophysiology:

Inflammatory back pain represents a chronic pain syndrome that originates from persistent immune mediated processes targeting the axial skeleton. The disorder arises when a systemic inflammatory response becomes focused within spinal and sacroiliac tissues, producing a local accumulation of cytokines and immune cells that alter the normal homeostasis of entheses, synovium, and subchondral bone. The resulting molecular milieu favors a sustained proinflammatory state characterized by upregulation of mediators such as tumor necrosis factor and interleukin 17, among others, which in turn drive local cellular activation, matrix degradation, and dysregulated bone turnover. This inflammatory persistence establishes a feed forward loop in which immune effectors and resident stromal cells perpetuate nociceptive signaling while simultaneously provoking structural change. The net consequence is a pathologic cycle of bone resorption and aberrant new bone formation that underpins both the symptom burden and the progressive loss of spinal mobility observed in advanced cases. Ankylosing spondylitis typifies the prototypical pathological process by which axial inflammation produces characteristic structural sequelae. In this context the disease process engages not only articular cartilage and subchondral bone but also the entheses, the fibrocartilaginous insertion sites of tendons and ligaments. Innate immune activation at these sites, potentially amplified by microbial antigens and pattern recognition receptor signaling, recruits lymphoid and myeloid populations that secrete cytokines fostering osteoclastogenesis and osteoblast modulation. The human leukocyte antigen B27 molecule influences multiple pathogenic pathways through effects on antigen presentation, peptide misfolding, and endoplasmic reticulum stress responses, and it thereby contributes to immune dysregulation in many affected individuals. Non HLA

genetic factors also participate by modifying immune thresholds and tissue responses. Mechanical stress superimposed on susceptible entheses appears to provoke focal inflammatory amplification and generation of IL 17 producing cells, coupling biomechanical forces to immunopathology. Over time the interplay of erosion and new bone deposition produces syndesmophyte formation and, in some cases, bridging ossification that culminates in the radiographic phenotype of vertebral fusion [9].



Figure-2: Pathophysiology of Spondyloarthritis (inflammatory backpain).

Psoriatic arthritis manifests overlapping axial pathology in a subset of patients and illustrates how cutaneous and synovial immune responses converge on spinal structures. Genetic predisposition remains evident in familial aggregation and concordance studies, and specific histocompatibility antigens correlate with risk. Environmental triggers such as skin infections, trauma, and dysbiosis may expose antigens or modify local immune responses, precipitating a shared inflammatory cascade in skin and joint compartments. The synovial and enthesial infiltrates observed in psoriatic disease contain parallel cell populations and cytokine signatures to those found in axial spondyloarthritis, supporting common effector mechanisms that can produce axial pain and structural change. Enteropathic arthropathy exemplifies the gut joint connection that contributes to axial inflammation in some patients. Experimental data from HLA B27 transgenic animals raised in germ free conditions demonstrate that microbial exposure is necessary for the development of intestinal and articular inflammation, implicating the microbiome as a critical environmental cofactor in disease induction [10]. Clinical serologic studies have identified heightened immune reactivity to intestinal and bacterial antigens, including antibodies directed at collagen subtypes and Klebsiella pneumoniae antigens in individuals with Crohn disease and ankylosing spondylitis, suggesting antigenic cross reactivity or molecular mimicry that bridges gut and joint immunity [11]. These observations provide a mechanistic rationale for how mucosal immune perturbation can translate into sustained axial inflammation and subsequent structural damage [10][11].

In juvenile idiopathic arthritis with axial involvement the pathogenic sequence begins within the synovium where proliferative inflamed pannus forms. Synoviocyte hyperplasia, neoangiogenesis, and infiltration by macrophages and lymphocytes generate a destructive front that advances onto articular cartilage. Cytokines, adhesion molecules, and chemokines orchestrate leukocyte recruitment and retention, while enzymatic degradation at pannus cartilage interfaces results in focal cartilage loss and remodeling. The chronicity of this synovial aggression lays the foundation for persistent pain and for secondary changes in subchondral bone architecture [12]. Reactive arthritis illustrates a postinfectious pathway to axial inflammation in which antecedent enteric or genitourinary infections with organisms such as Campylobacter, Salmonella, and Shigella incite an aberrant immune response that localizes to joints. Pathogen derived antigens or immune complexes may persistently stimulate host immunity, generating enthesitis and synovitis in predisposed individuals [13]. The resulting inflammatory cascade shares common downstream effectors with other spondyloarthropathies, including activation of osteoclasts and modulation of osteoblast activity, thus contributing to the characteristic pattern of coexisting bone loss and pathological ossification [12][13].

Across these syndromes the central pathogenic paradigm is one of immune driven tissue change coupled to dysregulated bone remodeling. Cytokine networks promote osteoclast mediated bone resorption in some microenvironments while promoting ectopic bone formation in others, producing the paradox of simultaneous bone loss and heterotopic ossification. Vascular changes, altered innervation, and persistent nociceptor sensitization amplify symptom chronicity. Recognition of these molecular and tissue level processes has directed the development of targeted therapies that interrupt specific cytokine pathways, aim to reduce inflammation, and limit structural progression. Continued elucidation of the roles played by host genetics, microbiota, mechanical stress, and local stromal responses remains essential to refine strategies

that prevent the transition from inflammatory activity to irreversible structural fusion and to restore functional capacity in affected individuals [11][12][13].

Histopathology

Inflammatory back pain, while not diagnostic in itself, is recognized as an early indicator of the pathological processes underlying seronegative spondyloarthropathies. Histopathologic evaluation of affected tissues demonstrates distinct inflammatory and structural alterations that differentiate these disorders from other chronic arthritides, such as rheumatoid arthritis. Comparative analyses show that patients with spondyloarthropathies exhibit marked synovial vascular proliferation, the accumulation of CD163-positive macrophages, and increased numbers of polymorphonuclear leukocytes within inflamed tissue, reflecting an active and sustained inflammatory response [14]. The synovial membrane in individuals with inflammatory back pain undergoes notable hyperplasia and thickening, primarily driven by infiltration of immune effector cells, including T lymphocytes, B lymphocytes, and macrophages. These cells constitute a dense inflammatory infiltrate within the synovial stroma, actively releasing a network of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukins IL-1, IL-6, and IL-17. The persistent release of these mediators perpetuates synovial inflammation, promoting angiogenesis and further recruitment of immune cells. This ongoing inflammatory process contributes to local edema, tissue remodeling, and eventual joint structure distortion. The hypervascular synovial tissue facilitates immune cell trafficking and sustains chronic inflammation, setting the stage for progressive tissue injury and bone involvement [14].

Beyond synovial inflammation, histopathologic evidence demonstrates the extension of the inflammatory process into subchondral bone. This involvement is characterized by the activation of osteoclasts, the primary bone-resorbing cells, which are stimulated by cytokine signaling from infiltrating macrophages and T cells. TNF-α, together with receptor activator of nuclear factor kappa-B ligand (RANKL), serves as a potent osteoclastogenic signal that enhances bone resorption at the entheses and subchondral margins. Over time, this process results in cortical bone erosion and loss of structural integrity. The continuous cycle of inflammation and bone remodeling contributes to the hallmark radiographic features observed in spondyloarthropathies, including erosion, sclerosis, and eventual ankylosis of affected joints. Microscopic analysis also highlights increased fibroblast proliferation and matrix metalloproteinase activity within the affected tissues. These factors facilitate extracellular matrix degradation and synovial pannus formation, further driving cartilage and bone destruction. The transition from inflammatory to reparative phases involves fibrotic replacement and aberrant bone formation, consistent with the clinical observation of syndesmophyte development and vertebral fusion in advanced disease stages. Thus, the histopathologic profile of inflammatory back pain underscores the integrated immune, vascular, and bone remodeling responses that define seronegative spondyloarthropathies. The interplay between cytokine-mediated inflammation, osteoclast activation, and aberrant tissue repair forms the biological basis for chronic pain, structural deformity, and progressive spinal stiffness characteristic of these conditions [14].

History and Physical:

Inflammatory back pain presents with a distinct clinical profile that enables its differentiation from mechanical etiologies of back pain. The onset is gradual rather than acute, with symptoms developing insidiously over weeks or months. Patients typically report deep, dull pain localized to the lower back or buttock region, often alternating sides. The discomfort characteristically improves with physical activity or stretching and worsens with prolonged rest or inactivity, a pattern opposite to that observed in degenerative or mechanical back disorders. Nocturnal pain is common and frequently disrupts sleep, yet patients often note relief upon waking and engaging in movement, highlighting the inflammatory rather than mechanical nature of the condition. During history taking, the clinician should assess chronicity, as IBP generally persists for three months or longer, with onset typically occurring before the age of forty. A detailed review of systems is essential to identify potential extra-articular manifestations such as enthesitis, uveitis, psoriasis, or gastrointestinal symptoms, which may indicate an underlying spondyloarthropathy. Many patients describe morning stiffness lasting more than thirty minutes that gradually resolves with activity, reflecting the presence of inflammatory mediators in the affected joints and surrounding soft tissues [14].

Physical examination focuses on evaluating spinal mobility, sacroiliac tenderness, and postural alignment. The Schober test and modified lumbar flexion assessments help detect reduced spinal flexibility, while palpation of the sacroiliac joints may elicit tenderness consistent with sacroiliitis. Observation of spinal curvature, chest expansion, and gait pattern provides additional diagnostic insight, particularly in advanced cases where spinal rigidity or kyphosis develops. The association of IBP with seronegative spondyloarthropathies underscores the potential contribution of systemic inflammation or a preceding infectious or autoimmune event [3]. Identifying these features through a meticulous history and targeted physical examination is critical for early recognition, differential diagnosis, and initiation of appropriate management strategies that can prevent progression and irreversible structural damage [3].

Evaluation and Diagnosis:

When inflammatory back pain (IBP) is clinically distinguished from other causes of spinal pain using accepted criteria, it serves as a pragmatic trigger for expedited rheumatologic assessment. Diagnostic evaluation integrates clinical phenotype, laboratory markers, and targeted imaging. The concurrence of characteristic IBP features with a positive HLA-B27 test and imaging evidence of sacroiliitis substantially raises the probability of an axial spondyloarthropathy and justifies specialist referral. Clinicians should therefore apply a probabilistic framework: combine history and physical findings with focused investigations to determine need for rheumatology consultation and advanced imaging. Laboratory testing contributes important but nonspecific information. An elevated erythrocyte sedimentation rate or C-reactive protein level reflects an acute phase response in up to half of patients with axial spondyloarthropathy, supporting an inflammatory etiology when present [15][16]. However, these markers lack disease specificity and may be raised in rheumatoid arthritis and other inflammatory states. Routine blood work should include complete blood count, liver and renal function tests, and serologies to exclude alternative diagnoses. Autoantibody testing such as rheumatoid factor and anti-cyclic citrullinated peptide antibodies aids differentiation from seropositive rheumatoid disease. In juvenile presentations, antinuclear antibody testing, marked elevation of ESR, hypergammaglobulinemia, and anemia provide supportive data and influence diagnostic weighting [12].

Physical examination yields dynamic measures of spinal mobility and focal tenderness that inform diagnostic probability and baseline function. The Schober test remains a simple bedside assessment of lumbar flexion. Measurement of distance between marked points on the lower back during maximal forward flexion quantifies lumbar range; an increase of less than 5 cm is considered positive and indicates restricted lumbar mobility consistent with ankylosing involvement [17]. Additional clinical maneuvers assess chest expansion, thoracic mobility, and sacroiliac tenderness. Documentation of morning stiffness duration and the pattern of pain improvement with exercise further refines the pretest likelihood of inflammatory pathology. Imaging is essential to confirm structural or active inflammatory changes and to stage disease. Conventional radiography of the sacroiliac joints and lumbar spine identifies chronic structural features such as joint space narrowing, sclerosis, erosions, and eventual bony ankylosis. Plain films may be insensitive early in the disease course, therefore early-stage inflammatory changes often require advanced imaging. Magnetic resonance imaging (MRI) provides superior sensitivity for active sacroiliitis. MRI detects bone marrow edema, osteitis, capsulitis, synovitis, and enthesitis prior to the development of chronic radiographic lesions. In ankylosing spondylitis and related conditions, MRI findings such as bone marrow edema in the iliac and sacral regions support the diagnosis and can precede radiographic fusion. Computed tomography offers high-resolution depiction of chronic bony change but is less useful for detecting active inflammatory edema. For enteropathic arthropathy, MRI is recommended in patients with concurrent inflammatory bowel disease and back pain, as it reveals active joint and periarticular changes even when plain films remain normal. Ultrasound may complement evaluation by identifying peripheral enthesitis and inflammatory soft tissue changes, particularly where accessible and when clinical suspicion for enthesopathy is high[15][16].

Diagnostic criteria combine clinical and imaging elements to establish specific diagnoses. For ankylosing spondylitis, classification typically requires at least one clinical feature alongside one imaging criterion that meets defined severity and duration thresholds. The ASAS criteria and modified New York criteria remain commonly referenced frameworks, and their application should follow current consensus guidance. In ambiguous cases or early presentations without definitive imaging, repeat clinical assessment and interval imaging may be necessary to capture evolving pathology. Differential diagnosis must be explicit and actively excluded. Mechanical lumbar disease, degenerative spondylosis, infection, malignancy, and inflammatory arthritides such as rheumatoid arthritis warrant consideration. Directed testing for infectious etiologies, malignancy screening when indicated, and prompt identification of red flags are essential to patient safety. Finally, the evaluation process should culminate in a clear disposition: patients with high clinical likelihood, positive HLA-B27, or MRI evidence of sacroiliitis should be referred to rheumatology for diagnostic confirmation and therapeutic planning. Those with indeterminate findings require close follow-up, repeat imaging, or multidisciplinary review. A structured pathway that integrates clinical scoring, selective laboratory testing, and tiered imaging optimizes early detection, guides appropriate specialist referral, and reduces diagnostic delay that contributes to irreversible structural progression [12][15][16].

Treatment / Management

Management of inflammatory back pain (IBP) requires a coordinated, evidence-informed strategy that integrates early specialist referral, individualized symptom control, disease-modifying therapy where indicated, rehabilitative intervention, and longitudinal monitoring. When clinical criteria for IBP are met and supportive findings such as a positive HLA-B27 test or imaging evidence of sacroiliitis are present, prompt referral to a rheumatologist is warranted to confirm diagnosis, stage disease, and initiate an appropriate therapeutic plan. Early specialist involvement facilitates timely initiation of targeted therapies, establishes a baseline for disease activity and structural status, and enables implementation of preventative measures against

irreversible complications. Initial management centers on patient education and risk modification. Clinicians should provide clear explanation of the inflammatory nature of the condition, likely clinical course, potential extraarticular associations, and the rationale for proposed investigations and therapies. Smoking cessation must be strongly advised because tobacco use is associated with increased disease activity and poorer therapeutic responses. Assessment of psychosocial needs and linkage to support services are essential components of care, as depression, anxiety, and social determinants influence adherence and outcomes. Physical therapy consultation should be arranged early; structured exercise, posture training, and mobility programs reduce pain, preserve spinal flexibility, and counteract functional decline characteristic of axial disease [18].



Figure-3: Treatment and Management of inflammatory backpain.

Symptomatic pharmacologic therapy ordinarily begins with a trial of nonsteroidal anti-inflammatory drugs administered at therapeutic dosing for two to four weeks to assess efficacy. An adequate trial at maximal tolerated dose is recommended because many patients attain meaningful symptomatic relief with NSAIDs alone. When NSAID therapy fails to control symptoms in a patient with confirmed axial spondyloarthropathy, escalation to biologic disease-modifying agents is indicated. Tumor necrosis factor inhibitors constitute first-line biologic therapy in many patients. Alternatives include monoclonal antibodies targeting interleukin-17 such as secukinumab, particularly when TNF inhibitors are contraindicated or ineffective [18]. Treatment decisions must incorporate patient comorbidities, reproductive plans, infection risk, and previous treatment responses. For patients who initially respond to a TNF inhibitor but later demonstrate secondary loss of efficacy, switching to another TNF inhibitor is an accepted strategy. If intolerance or inadequate response persists after one or two TNF inhibitors, transitioning to an anti-IL-17 agent such as ixekizumab or secukinumab, or to a Janus kinase inhibitor such as tofacitinib or upadacitinib, may be appropriate. Use of these immunomodulatory agents necessitates pretherapy screening for latent infections, malignancy assessment where indicated, vaccination review, and periodic monitoring of laboratory indices to detect hematologic, hepatic, or lipid abnormalities. Clinicians must carefully weigh the risks of immune suppression in patients with a history of demyelinating disease, severe cardiac dysfunction, active infection, or neoplasia [18].

Nonpharmacologic interventions are integral to durable disease control. Individualized exercise programs combine aerobic conditioning, spinal mobility exercises, and targeted strengthening to preserve function and enhance quality of life. Hydrotherapy and supervised group exercise may augment adherence and provide additional symptomatic benefit. Ergonomic advice, occupational therapy for work modifications, and vocational rehabilitation support reintegration into daily activities. Attention to bone health is mandatory; screening for osteoporosis, initiation of antiresorptive or anabolic therapy when indicated, and correction of vitamin D deficiency reduce fracture risk associated with chronic inflammation and immobility. Surgical intervention retains a defined role for selected complications and structural sequelae. Indications include severe, refractory hip arthropathy causing persistent incapacitating pain or loss of mobility, atlantoaxial instability with neurological compromise, and fixed severe kyphotic deformity that impairs horizontal gaze or pulmonary function. Decision making for operative treatment requires multidisciplinary assessment involving rheumatology, orthopaedic or spinal surgery, anesthesiology, and rehabilitation specialists to optimize timing, perioperative management, and postoperative rehabilitation [19][20].

Monitoring disease activity and outcomes is essential. Validated instruments such as the Bath Ankylosing Spondylitis Disease Activity Index and

functional indices enable objective appraisal of treatment response and guide therapeutic adjustments. Serial imaging is reserved for cases with clinical progression or diagnostic uncertainty; MRI serves to document active inflammation and to distinguish inflammatory flares from chronic structural change. Laboratory surveillance should include inflammatory markers and safety monitoring for patients on disease-modifying agents. Special populations require tailored considerations. In juvenile presentations, management emphasizes preservation of growth and joint integrity while controlling inflammation, using pediatric-appropriate dosing and monitoring [12]. Reproductive counseling is necessary for patients of childbearing potential because select agents carry teratogenic risk or require washout prior to conception. Vaccination optimization and infection prophylaxis are necessary before initiating biologic or targeted synthetic therapies.

Interprofessional collaboration underpins optimal management. Rheumatologists coordinate pharmacologic and diagnostic strategies, physical therapists operationalize exercise prescriptions, nurses provide medication education and monitor adverse effects, pharmacists perform medication reconciliation and counsel on interactions, and social workers address access barriers. Health information workers facilitate continuity by ensuring accurate documentation, tracking outcome measures, and supporting recall systems for monitoring and vaccination. Taken together, management of IBP demands an integrated model that combines early diagnosis, patient education, targeted pharmacotherapy, structured rehabilitation, and vigilant monitoring. Individualized care plans that incorporate patient preferences, comorbidity management, and clear pathways for escalation of therapy maximize functional outcomes and reduce the risk of structural progression. Successful long-term management rests on the synergy of specialist expertise, rehabilitative services, and coordinated multidisciplinary support [9][12][21].

Differential Diagnosis

The differential diagnosis of inflammatory back pain (IBP) is broad and requires systematic exclusion of mechanical, nonmechanical, and visceral causes of back pain. The goal is to differentiate inflammatory disease from degenerative, infectious, or malignant conditions that may mimic its presentation. Recognizing key distinguishing features prevents diagnostic delays and unnecessary treatment. Mechanical back pain represents the most common alternative diagnosis. It usually arises from muscle strain, ligament sprain, disc degeneration, or facet joint dysfunction. Patients often report a specific inciting event or repetitive activity associated with pain onset. The pain worsens with movement, bending, or lifting and improves with rest. Unlike IBP, mechanical pain rarely causes significant morning stiffness and does not improve with exercise. Radiographic imaging in mechanical pain typically shows degenerative changes such as disc space narrowing, osteophyte formation, or facet arthropathy. Malignancy must always be considered, especially in patients with a history of cancer, unexplained weight loss, or age over 50. Metastatic disease from breast, prostate, lung, thyroid, or kidney cancers commonly affects the spine. Pain from spinal metastasis is constant, progressive, and often nocturnal, without relief from rest or movement. In one study, a prior history of malignancy and strong clinical suspicion were the most significant predictors of cancer-related back pain [23]. MRI is the preferred diagnostic tool for detecting spinal metastases, as it reveals marrow involvement and epidural extension before radiographic changes appear [23].

Infectious causes such as vertebral osteomyelitis and epidural abscess must be rapidly identified. Clinical clues include fever, recent infection, immunosuppression, or intravenous drug use. Pain is severe, localized, and persistent, often accompanied by elevated inflammatory markers. MRI with contrast is mandatory when infection is suspected, as early detection prevents irreversible neurological damage. Compression fractures, particularly in elderly patients or those with osteoporosis or chronic corticosteroid use, may present with acute localized pain following minor trauma. Radiographs or computed tomography confirm the diagnosis by revealing vertebral height loss or cortical disruption. Visceral and referred pain sources must also be considered. Aortic aneurysm, pancreatitis, nephrolithiasis, and gynecologic disorders may present with back pain mimicking musculoskeletal causes. Detailed history and focused physical examination, along with targeted laboratory and imaging studies, are necessary to identify these conditions. Neurologic evaluation remains essential in all patients. Motor weakness, sensory changes, or bowel and bladder dysfunction may indicate spinal cord compression or cauda equina syndrome, requiring urgent MRI and surgical consultation. Distinguishing IBP from these alternative causes relies on characteristic features: onset before age 40, duration longer than 3 months, gradual progression, morning stiffness exceeding 30 minutes, and improvement with exercise rather than rest. These diagnostic hallmarks, combined with targeted imaging and laboratory investigations, enable accurate differentiation of inflammatory pathology from mechanical, infectious, or neoplastic etiologies [22][23].

Prognosis

The prognosis of inflammatory back pain (IBP) depends largely on the underlying condition, disease severity, response to therapy, and adherence to long-term management strategies. Although IBP itself is not directly associated with increased mortality, its link to seronegative spondyloarthropathies, such as ankylosing spondylitis and psoriatic arthritis,

introduces the potential for systemic complications and progressive structural damage if not properly managed. Early recognition and intervention are key factors influencing long-term outcomes and functional preservation. Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the cornerstone of IBP treatment. These agents not only alleviate pain but also reduce inflammation, improve spinal mobility, and decrease morning stiffness. Clinical evidence demonstrates that consistent NSAID use can enhance chest expansion and preserve spinal flexibility, improving daily function and quality of life [24][25]. When combined with supervised exercise programs and physical therapy, these interventions further strengthen musculoskeletal support and mitigate stiffness, resulting in better long-term physical outcomes. Patients adhering to combined pharmacologic and rehabilitative therapy generally report improved symptom control and reduced disease progression compared to those treated pharmacologically alone [24][25].

Beyond musculoskeletal improvement, long-term control of inflammation is crucial in mitigating systemic risks. Chronic inflammation associated with spondyloarthropathies increases the risk of cardiovascular disease. Studies indicate that patients with ankylosing spondylitis and related conditions face a 36% to 76% higher risk of developing acute coronary syndrome (ACS) and a 50% increased risk of venous thromboembolism [26]. This cardiovascular vulnerability arises from persistent inflammatory activity, endothelial dysfunction, and an increased prevalence of traditional risk factors such as hypertension and dyslipidemia. Female patients with psoriatic arthritis (PsA) experience particularly elevated cardiovascular risk, nearly doubling their likelihood of ACS compared with the general population [26]. Despite these associations, the absolute risk of major cardiovascular events in IBP populations remains modest, given that these disorders typically manifest in younger adults. Nevertheless, proactive cardiovascular risk management, including lifestyle modification, lipid control, and smoking cessation, should be integral to long-term care. Functional outcomes are generally favorable with early diagnosis and comprehensive management. However, delayed or inadequate treatment may lead to irreversible spinal stiffness, deformity, and disability. Patients with advanced ankylosing spondylitis may experience kyphotic posture and reduced pulmonary function due to thoracic involvement. Long-term prognosis improves significantly with adherence to therapy, multidisciplinary care, and regular monitoring of disease activity. Early use of biologic agents, when indicated, has demonstrated substantial benefits in preventing structural damage and maintaining function. With appropriate intervention and ongoing follow-up, most patients with IBP can maintain mobility, independence, and quality of life throughout the course of their disease [24][25][26].

Complications

The pathobiology of inflammatory back pain (IBP) predisposes patients to a spectrum of musculoskeletal, neurologic, renal, and systemic complications that accrue over time and materially affect morbidity. Chronic immunologically mediated inflammation disrupts normal bone homeostasis, creating a milieu in which osteoclastic resorption and aberrant osteoblastic activity coexist. This dysregulated remodeling manifests clinically as early osteoporosis and focal bone loss, changes that can be detected within the first decade following disease onset. The combination of reduced bone density and progressive structural alteration of the vertebral column markedly increases fracture susceptibility. Epidemiologic evidence indicates that patients with ankylosing spondylitis have approximately twice the risk of sustaining vertebral fractures compared with population controls, with a predilection for injuries in the cervical segment where mechanical stresses and existing structural rigidity combine to amplify vulnerability [27]. Vertebral fractures in this context often produce more severe sequelae than osteoporotic fractures in otherwise healthy individuals because of the altered biomechanics imparted by syndesmophytes and spinal rigidity [27].

Neurologic compromise represents a particularly consequential category of complications. The incidence of spinal cord injury is substantially elevated in ankylosing spondylitis, with some series reporting an approximate 11-fold increase relative to the general population. The risk stems from a confluence of factors including unstable fracture patterns, epidural hematoma formation following minor trauma, and progressive kyphotic deformity that concentrates stress on the cervical cord. Longstanding disease confers additional risk for compressive syndromes and for cauda equina dysfunction, the latter arising from chronic dural adhesions and inflammatory fibrosis within the lumbosacral canal. Neurologic deterioration in these patients can be rapid and catastrophic, mandating a low threshold for prompt neuroimaging and surgical consultation when new deficits emerge. Systemic organ involvement and comorbidities further compound long-term risk. Renal pathology is more prevalent among individuals with axial spondyloarthropathy, and cohort studies document a higher frequency of abnormal urinalysis findings compared with matched controls, suggesting an elevated risk for nephropathy. The etiologies are multifactorial and include chronic inflammation, amyloid deposition in protracted disease, and drug-related nephrotoxicity. Cardiovascular risk is also amplified; chronic systemic inflammation contributes to accelerated atherosclerosis, and the aggregate risk for acute coronary events and venous

thromboembolism is increased among patients with spondyloarthropathies, necessitating vigilant cardiovascular risk assessment and management [27].

Pharmacotherapy, while central to symptom control and disease modification, introduces its own risk profile. Long-term administration of nonsteroidal anti-inflammatory drugs, a mainstay of initial IBP management, is associated with gastrointestinal, cardiovascular, renal, and pulmonary adverse effects. NSAID exposure can precipitate or exacerbate peptic ulcer disease and gastrointestinal bleeding, especially in the presence of Helicobacter pylori infection or concurrent anticoagulant therapy. In patients with existing cardiovascular disease or significant risk factors, certain NSAIDs may elevate the risk of ischemic events, a consideration that requires individualized risk-benefit analysis. Renal impairment ranging from acute kidney injury to chronic renal insufficiency may occur, particularly in patients receiving concomitant nephrotoxic agents such as diuretics or angiotensin converting enzyme inhibitors and in those with baseline renal vulnerability. NSAIDs can also provoke bronchospasm in susceptible individuals with reactive airway disease. Clinical decision making around NSAID initiation and maintenance should therefore account for comorbid conditions and concurrent medications, including systemic glucocorticoids, anticoagulants, diuretics, and selective serotonin reuptake inhibitors, all of which modify bleeding, renal, or cardiovascular risk [31][32][33].

Fracture, neurologic injury, and systemic comorbidity compound the need for coordinated surveillance and timely intervention. Multidisciplinary consultation becomes essential when complications develop or when risk stratification indicates elevated vulnerability. Rheumatologic referral is indicated not only for diagnosis and disease-directed therapy but also for the longitudinal management of systemic complications and for coordinating advanced therapeutics that may modify structural progression. Orthopaedic and spinal surgical consultation is frequently required in the setting of unstable fractures, progressive kyphotic deformity that impairs function or respiration, or neurologic compromise such as myelopathy or cauda equina syndrome. Neurosurgical input is critical for the evaluation and management of spinal cord compression and epidural hematoma. Nephrology consultation is warranted for persistent renal abnormalities, progressive decline in renal function, or when drug toxicity is suspected. Cardiovascular specialists should be engaged when ischemic disease, thromboembolic events, or significant cardiovascular risk factors complicate the disease course [27][28][29][30].

Patient Education:

Deterrence and patient education constitute foundational strategies to mitigate the occurrence and impact of complications. Patient counseling should emphasize smoking cessation as an essential modifiable risk factor, given the association between tobacco use and worsened disease activity, reduce therapeutic responsiveness, and accelerate structural progression. Education must also address safe activity modification to reduce the likelihood of traumatic vertebral injury; patients should receive guidance on fall prevention, use of protective measures in high risk occupations or sports, and the avoidance of uncontrolled spinal loading. Proactive bone health management includes assessment of bone mineral density, optimization of calcium and vitamin D status, and initiation of antiresorptive or anabolic therapy when indicated to reduce fracture risk. Regular monitoring of renal function and gastrointestinal risk facilitates early detection of NSAID toxicity and supports timely therapeutic adjustment. Vaccination review, infection screening prior to immunosuppressive therapy, and counseling regarding signs of infection are imperative when advanced immunomodulatory agents are considered. Structured follow up and a multidisciplinary care plan align surveillance with timely specialty referral. Early physical therapy engagement focusing on spinal mobility, core strengthening, and postural training reduces functional decline and may decrease fracture risk by improving balance and reducing fall risk. Psychosocial support and occupational therapy optimize adaptation to chronic disability and sustain vocational function. In sum, the constellation of complications associated with IBP underscores the necessity of comprehensive, proactive management that integrates preventive measures, individualized pharmacologic strategies, vigilant monitoring, and timely multidisciplinary consultation to preserve function and minimize morbidity [27][31][32][33].

Conclusion:

In conclusion, Inflammatory Back Pain is a significant clinical syndrome requiring a proactive and integrated management strategy to alter its potentially debilitating course. Its strong association with seronegative spondyloarthropathies necessitates early recognition based on characteristic clinical features—such as chronicity, morning stiffness, and improvement with activity—to facilitate prompt rheumatologist referral and intervention. Effective management is fundamentally multidisciplinary, combining the expertise of physicians, physical therapists, nurses, and pharmacists. The treatment paradigm successfully integrates pharmacologic agents, from first-line NSAIDs to advanced biologic therapies, with essential non-pharmacologic components like structured exercise and patient education. The long-term prognosis for individuals with IBP is largely dependent on this early, comprehensive approach. Without it, patients face a substantial risk of progressive structural damage, including spinal fusion, osteoporosis, fractures, and systemic complications such as increased cardiovascular morbidity. Therefore, a coordinated,

interprofessional care model is not merely beneficial but essential. It ensures accurate diagnosis, timely initiation of disease-modifying therapy, sustained functional preservation, and improved quality of life, ultimately mitigating the significant personal and healthcare burdens associated with chronic inflammatory back pain.

References:

1. Zhao J, Chen J, Yang TH, Holme P. Insights into the pathogenesis of axial spondyloarthropathy from network and pathway analysis. BMC Syst Biol. 2012;6 Suppl 1(Suppl 1):S4.
2. Chyuan IT, Chen JY. Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies. Mediators Inflamm. 2018;2018:2403935.
3. Weisman MH. Inflammatory back pain: the United States perspective. Rheum Dis Clin North Am. 2012 Aug;38(3):501-12.
4. Braun J, Inman R. Clinical significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthritis. Ann Rheum Dis. 2010 Jul;69(7):1264-8.
5. Thomas GP, Duan R, Pettit AR, Weedon H, Kaur S, Smith M, Brown MA. Expression profiling in spondyloarthropathy synovial biopsies highlights changes in expression of inflammatory genes in conjunction with tissue remodelling genes. BMC Musculoskelet Disord. 2013 Dec 15;14:354.
6. Hamilton L, Macgregor A, Warmington V, Pinch E, Gaffney K. The prevalence of inflammatory back pain in a UK primary care population. Rheumatology (Oxford). 2014 Jan;53(1):161-4.
7. Lau IS, Gun SC, Yeap SS, Mohd Zain M, Mohd Yusoof H, Sargunan S, Yahya F. Algorithm for the referral of patients with inflammatory back pain from primary care in Malaysia. Malays Fam Physician. 2021 Jul 22;16(2):2-6.
8. Tam LS, Wei JC, Aggarwal A, Baek HJ, Cheung PP, Chiowchanwisawakit P, Dans L, Gu J, Hagino N, Kishimoto M, Reyes HM, Soroosh S, Stebbings S, Whittle S, Yeap SS, Lau CS. 2018 APLAR axial spondyloarthritis treatment recommendations. Int J Rheum Dis. 2019 Mar;22(3):340-356.
9. Parameswaran P, Lucke M. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 4, 2023. HLA-B27 Syndromes.
10. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernández-Sueiro JL, Balish E, Hammer RE. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994 Dec 01;180(6):2359-64.
11. Tiwana H, Natt RS, Benitez-Brito R, Shah S, Wilson C, Bridger S, Harbord M, Sarner M, Ebringer A. Correlation between the immune responses to collagens type I, III, IV and V and Klebsiella pneumoniae in patients with Crohn's disease and ankylosing spondylitis. Rheumatology (Oxford). 2001 Jan;40(1):15-23.
12. Thatayatikom A, Modica R, De Leucio A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 16, 2023. Juvenile Idiopathic Arthritis.
13. Ajene AN, Fischer Walker CL, Black RE. Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, salmonella and Shigella-associated reactive arthritis. J Health Popul Nutr. 2013 Sep;31(3):299-307.
14. Baeten D, Kruithof E, De Rycke L, Boots AM, Mielants H, Veys EM, De Keyser F. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther. 2005;7(2):R359-69.
15. Brandt HC, Spiller I, Song IH, Vahldiek JL, Rudwaleit M, Sieper J. Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis. 2007 Nov;66(11):1479-84.
16. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sørensen IJ, Ozgocmen S, Roussou E, Valle-Oñate R, Weber U, Wei J, Sieper J. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009 Jun;68(6):777-83.
17. Wang Z, Du M, Li J, Shi D, Wang H, Li H, Guo H. Clinical study of Tongdu Shujin decoction in the treatment of ankylosing spondylitis with cold-dampness obstruction type: Study protocol for a randomized controlled trial. Medicine (Baltimore). 2023 Feb 10;102(6):e32852.
18. Aboobacker S, Kurn H, Al Aboud AM. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 20, 2023. Secukinumab.
19. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun;76(6):978-991.
20. Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A,

Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan;77(1):3-17.

21. Malik TF, Aurelio DM. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Mar 6, 2023. Extraintestinal Manifestations of Inflammatory Bowel Disease.
22. Wahl EC, Smith D, Sesto M, Boissonnault W. Differential diagnosis of a patient with low back and toe pain. J Man Manip Ther. 2013 May;21(2):81-9.
23. Verhagen AP, Downie A, Maher CG, Koes BW. Most red flags for malignancy in low back pain guidelines lack empirical support: a systematic review. Pain. 2017 Oct;158(10):1860-1868.
24. Wong JJ, Côté P, Sutton DA, Randhawa K, Yu H, Varatharajan S, Goldgrub R, Nordin M, Gross DP, Shearer HM, Carroll LJ, Stern PJ, Ameis A, Southerst D, Mior S, Stupar M, Varatharajan T, Taylor-Vaisey A. Clinical practice guidelines for the noninvasive management of low back pain: A systematic review by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration. Eur J Pain. 2017 Feb;21(2):201-216.
25. Kroon FP, van der Burg LR, Ramiro S, Landewé RB, Buchbinder R, Falzon L, van der Heijde D. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015 Jul 17;2015(7):CD010952.
26. Wang R, Ward MM. Epidemiology of axial spondyloarthritis: an update. Curr Opin Rheumatol. 2018 Mar;30(2):137-143.
27. Chaudhary SB, Hullinger H, Vives MJ. Management of acute spinal fractures in ankylosing spondylitis. ISRN Rheumatol. 2011;2011:150484.
28. Moltó A, Etcheto A, van der Heijde D, Landewé R, van den Bosch F, Bautista Molano W, Burgos-Vargas R, Cheung PP, Collantes-Estevez E, Deodhar A, El-Zorkany B, Erdes S, Gu J, Hajjaj-Hassouni N, Kiltz U, Kim TH, Kishimoto M, Luo SF, Machado PM, Maksymowych WP, Maldonado-Cocco J, Marzo-Ortega H, Montecucco CM, Ozgoçmen S, van Gaalen F, Dougados M. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis. 2016 Jun;75(6):1016-23.
29. Mundwiler ML, Siddique K, Dym JM, Perri B, Johnson JP, Weisman MH. Complications of the spine in ankylosing spondylitis with a focus on deformity correction. Neurosurg Focus. 2008;24(1):E6.
30. Lee SH, Lee EJ, Chung SW, Song R, Moon JY, Lee SH, Lim SJ, Lee YA, Hong SJ, Yang HI. Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker. Rheumatol Int. 2013 Jul;33(7):1689-92
31. Walker C, Biasucci LM. Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited. Postgrad Med. 2018 Jan;130(1):55-71.
32. Shim YK, Kim N. [Nonsteroidal Anti-inflammatory Drug and Aspirin-induced Peptic Ulcer Disease]. Korean J Gastroenterol. 2016 Jun 25;67(6):300-12.
33. Lassiter, William, Beenish S. Bhutta, and Abdallah E. Allam. "Inflammatory back pain." In *StatPearls [Internet]*. Statpearls Publishing, 2024.